FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246016093> ?p ?o ?g. }

• W4246016093 endingPage "34" @default.
• W4246016093 startingPage "29" @default.
• W4246016093 abstract "Drug-eluting stents have been used since 2002 in different patient populations aiming to achieve high success rates with low clinical and angiographic restenosis rates. With the late thrombosis adverse events associated to the first generation sirolimus and paclitaxel-eluting stents, second-generation everolimus and zotarolimus-eluting stents has been recently developed. The POLAR registry is a prospective, non-randomized, multicenter study, which included 988 patients, totaling 1,362 lesions treated with the everolimus-eluting stent Promus®. In order to represent the clinical practice, almost all subtypes of patients and lesions were included in this registry. Clinical follow-up was planned to be performed 1, 6, 12 and 24 months after the procedure. Most patients were male (69.8%), with mean age of 64.9 ± 9.4 years, 35.2% were diabetics and 55% had been treated for acute coronary syndrome. Vessel diameter was 2.95 ± 0.43 mm and lesion extension was 20.5 ± 5.6 mm. A total of 1.14 ± 0.38 stent/patient were implanted and the procedural success rate was 96.6%. Major adverse cardiac events occurred in 4.5% of patients, and stent thrombosis was observed in 5 patients (0.5%) after a clinical follow-up of 12 months. The present registry suggests that everolimus-eluting stents are safe and effective in daily clinical practice patients, with a low rate of major adverse cardiac events at the end of the first year of follow-up. Resultados Clínicos de Um Ano do Registro POLAR (PrOmus eluting stent registry in Latin AmeRica) Desde 2002, os stents farmacológicos são utilizados em diversas populações de pacientes objetivando alcançar elevados índices de sucesso, com baixas taxas de reestenose angiográfica e clínica. Com os resultados adversos em relação à trombose tardia associados aos stents farmacológicos de primeira geração eluidores de sirolimus e paclitaxel, surgiram recentemente os stents farmacológicos de segunda geração eluidores de zotarolimus e everolimus. O registro POLAR é um registro prospectivo, não randomizado, multicêntrico, que incluiu 988 pacientes totalizando 1.362 lesões tratadas com o stent Promus®. Objetivando representar a prática clínica, praticamente todos os subtipos de pacientes e lesões foram incluídos neste registro. O seguimento clínico foi planejado para ser realizado 1 mês, 6 meses, 12 meses e 24 meses após o procedimento. A maioria dos pacientes era do sexo masculino (69,8%), com média de idade de 64,9 ± 9,4 anos, 35,2% eram diabéticos e 55% tinham sido tratados na vigência de síndrome coronária aguda. O diâmetro do vaso foi de 2,95 ± 0,43 mm e a extensão da lesão, de 20,5 ± 5,6 mm. Foi implantado 1,14 ± 0,38 stent/paciente e o sucesso do procedimento foi alcançado em 96,6% dos casos. Eventos cardíacos adversos maiores ocorreram em 4,1% dos pacientes, e trombose de stent esteve presente em 5 pacientes (0,5%) após o seguimento clínico de 12 meses. O presente registro sugere que os stents farmacológicos eluidores de everolimus são seguros e eficazes em pacientes da prática clínica diária, com baixas taxas de eventos cardíacos adversos maiores ao término do primeiro ano de seguimento." @default.
• W4246016093 created "2022-05-12" @default.
• W4246016093 creator A5001053368 @default.
• W4246016093 creator A5017997003 @default.
• W4246016093 creator A5025873567 @default.
• W4246016093 creator A5032059992 @default.
• W4246016093 creator A5044646469 @default.
• W4246016093 creator A5053065592 @default.
• W4246016093 creator A5056349768 @default.
• W4246016093 creator A5060507539 @default.
• W4246016093 creator A5070999274 @default.
• W4246016093 creator A5075854254 @default.
• W4246016093 creator A5077826782 @default.
• W4246016093 creator A5083400941 @default.
• W4246016093 creator A5087705533 @default.
• W4246016093 creator A5091796858 @default.
• W4246016093 date "2012-01-01" @default.
• W4246016093 modified "2023-10-01" @default.
• W4246016093 title "POLAR Registry (Promus eluting stent registry in Latin America): 1 year Follow-up Results" @default.
• W4246016093 doi "https://doi.org/10.1016/s0104-1843(12)50007-x" @default.
• W4246016093 hasPublicationYear "2012" @default.
• W4246016093 type Work @default.
• W4246016093 citedByCount "0" @default.
• W4246016093 crossrefType "journal-article" @default.
• W4246016093 hasAuthorship W4246016093A5001053368 @default.
• W4246016093 hasAuthorship W4246016093A5017997003 @default.
• W4246016093 hasAuthorship W4246016093A5025873567 @default.
• W4246016093 hasAuthorship W4246016093A5032059992 @default.
• W4246016093 hasAuthorship W4246016093A5044646469 @default.
• W4246016093 hasAuthorship W4246016093A5053065592 @default.
• W4246016093 hasAuthorship W4246016093A5056349768 @default.
• W4246016093 hasAuthorship W4246016093A5060507539 @default.
• W4246016093 hasAuthorship W4246016093A5070999274 @default.
• W4246016093 hasAuthorship W4246016093A5075854254 @default.
• W4246016093 hasAuthorship W4246016093A5077826782 @default.
• W4246016093 hasAuthorship W4246016093A5083400941 @default.
• W4246016093 hasAuthorship W4246016093A5087705533 @default.
• W4246016093 hasAuthorship W4246016093A5091796858 @default.
• W4246016093 hasBestOaLocation W42460160931 @default.
• W4246016093 hasConcept C126322002 @default.
• W4246016093 hasConcept C141071460 @default.
• W4246016093 hasConcept C168563851 @default.
• W4246016093 hasConcept C197934379 @default.
• W4246016093 hasConcept C203092338 @default.
• W4246016093 hasConcept C2777546689 @default.
• W4246016093 hasConcept C2777921159 @default.
• W4246016093 hasConcept C2778283817 @default.
• W4246016093 hasConcept C2778583881 @default.
• W4246016093 hasConcept C2779699572 @default.
• W4246016093 hasConcept C2780797203 @default.
• W4246016093 hasConcept C71924100 @default.
• W4246016093 hasConceptScore W4246016093C126322002 @default.
• W4246016093 hasConceptScore W4246016093C141071460 @default.
• W4246016093 hasConceptScore W4246016093C168563851 @default.
• W4246016093 hasConceptScore W4246016093C197934379 @default.
• W4246016093 hasConceptScore W4246016093C203092338 @default.
• W4246016093 hasConceptScore W4246016093C2777546689 @default.
• W4246016093 hasConceptScore W4246016093C2777921159 @default.
• W4246016093 hasConceptScore W4246016093C2778283817 @default.
• W4246016093 hasConceptScore W4246016093C2778583881 @default.
• W4246016093 hasConceptScore W4246016093C2779699572 @default.
• W4246016093 hasConceptScore W4246016093C2780797203 @default.
• W4246016093 hasConceptScore W4246016093C71924100 @default.
• W4246016093 hasIssue "1" @default.
• W4246016093 hasLocation W42460160931 @default.
• W4246016093 hasOpenAccess W4246016093 @default.
• W4246016093 hasPrimaryLocation W42460160931 @default.
• W4246016093 hasRelatedWork W145977013 @default.
• W4246016093 hasRelatedWork W2006600086 @default.
• W4246016093 hasRelatedWork W2074384350 @default.
• W4246016093 hasRelatedWork W2139912741 @default.
• W4246016093 hasRelatedWork W2156495621 @default.
• W4246016093 hasRelatedWork W2226144646 @default.
• W4246016093 hasRelatedWork W2414576070 @default.
• W4246016093 hasRelatedWork W2548677575 @default.
• W4246016093 hasRelatedWork W2777748294 @default.
• W4246016093 hasRelatedWork W3036698923 @default.
• W4246016093 hasVolume "20" @default.
• W4246016093 isParatext "false" @default.
• W4246016093 isRetracted "false" @default.
• W4246016093 workType "article" @default.